Al-Daghri Nasser M, Al-Saleh Yousef, Aljohani Naji, Sulimani Riad, Al-Othman Abdulaziz M, Alfawaz Hanan, Fouda Mona, Al-Amri Fahad, Shahrani Awad, Alharbi Mohammed, Alshahrani Fahad, Tamimi Waleed, Sabico Shaun, Rizzoli Rene, Reginster Jean-Yves
Prince Mutaib Chair for Biomarkers of Osteoporosis, Biochemistry Department, College of Science, King Saud University, Riyadh, 11451, Saudi Arabia.
Biomarkers Research Program, Biochemistry Department, College of Science, King Saud University|, PO Box, 2455, Riyadh, 11451, Saudi Arabia.
Arch Osteoporos. 2017 Dec;12(1):1. doi: 10.1007/s11657-016-0295-y. Epub 2016 Dec 21.
Vitamin D deficiency is common in the Middle East and in Saudi Arabia, in particular. While several international recommendations on the management of vitamin D deficiency have been documented and practiced globally, these recommendations should be adapted to the conditions of the Middle Eastern region. To address this challenge, the Prince Mutaib Chair for Biomarkers of Osteoporosis (PMCO) in King Saud University (KSU), Riyadh, KSA, together with local experts and in cooperation with the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO), organized a panel that formulated unified recommendations in the diagnosis and treatment of vitamin D deficiency in the region.
The selection of local and international experts commenced during the 2nd International Vitamin D Symposium conducted in Riyadh, Saudi Arabia, last January 20--21, 2016. Reviews of the most recent literature were done, and face-to-face meetings were conducted for revisions and final recommendations.
Vitamin D sufficiency is defined as circulating serum 25(OH)D ≥50 nmol (≥20 ng/ml) for the general population and vitamin D adequacy as serum 25(OH)D >75 nmol/L l (>30 ng/ml) for the frail and osteoporotic elderly. Despite overwhelming prevalence of vitamin D deficiency, universal screening is not recommended. Recommendations for the general population, children, pregnant/lactating women, post-menopausal women, the elderly, and those with subsequent metabolic diseases were provided.
Vitamin D sufficiency is defined as circulating serum 25(OH)D ≥50 nmol (≥20 ng/ml) for the general population and vitamin D adequacy as serum 25(OH)D >75 nmol/L l (>30 ng/ml) for the frail and osteoporotic elderly. Despite overwhelming prevalence of vitamin D deficiency, universal screening is not recommended. Recommendations for the general population, children, pregnant/lactating women, post-menopausal women, the elderly, and those with subsequent metabolic diseases were provided.
Vitamin D supplementation/correction is advised in all persons whose serum 25(OH)D falls below 50 nmol/l (20 ng/ml), and achieving a target of 75 nmol/l (30 ng/ml) is particularly suited for frail, osteoporotic, and older patients. Conducting well-designed clinical trials in the region that will address economic implications and investigations on the treatment persistence and compliance to vitamin D treatment in the region are encouraged.
维生素D缺乏在中东地区很常见，在沙特阿拉伯尤为如此。虽然全球已记录并实施了多项关于维生素D缺乏管理的国际建议，但这些建议应根据中东地区的情况进行调整。为应对这一挑战，沙特阿拉伯利雅得国王沙特大学（KSU）的穆泰卜骨质疏松生物标志物主席（PMCO）与当地专家合作，并与欧洲骨质疏松症和骨关节炎临床与经济学会（ESCEO）共同组织了一个小组，制定了该地区维生素D缺乏诊断和治疗的统一建议。
在2016年1月20 - 21日于沙特阿拉伯利雅得举行的第二届国际维生素D研讨会上开始挑选当地和国际专家。对最新文献进行了综述，并举行了面对面会议以进行修订和最终确定建议。
一般人群的维生素D充足定义为循环血清25(OH)D≥50 nmol（≥20 ng/ml），体弱和骨质疏松的老年人维生素D充足定义为血清25(OH)D>75 nmol/L（>30 ng/ml）。尽管维生素D缺乏普遍存在，但不建议进行普遍筛查。提供了针对一般人群、儿童、孕妇/哺乳期妇女、绝经后妇女、老年人以及患有后续代谢疾病者的建议。
建议血清25(OH)D低于50 nmol/l（20 ng/ml）的所有人补充/纠正维生素D，对于体弱、骨质疏松和老年患者，将目标设定为75 nmol/l（30 ng/ml）尤为合适。鼓励在该地区开展精心设计的临床试验，以解决经济影响以及对该地区维生素D治疗的持续性和依从性进行调查。
